AstraZeneca stock is holding steady, with a 10% increase year to date. The company is developing weight loss products and cancer drugs, with a breast cancer treatment already generating $302 million in sales. A new drug in trials could bring in $6 billion by 2030.

Analysts believe AstraZeneca’s oncology portfolio will drive major cash flows despite competition. The company has invested $50 billion in its US expansion, signaling a potential shift. With a focus on cancer treatment, AstraZeneca aims to reach $80 billion in revenue by 2030, targeting the UK market’s high demand.

Read more at Morningstar: Are AstraZeneca Shares a Buy?